Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), one of the crucial pro-angiogenic factors, functions as a potent inhibitor of endothelial cell (EC) apoptosis. Previous progress has been made towards delineating the VPF/VEGF survival signaling downstream of the activation of VEGFR-2. Here, we seek to define the function of NRP-1 in VPF/VEGF-induced survival signaling in EC and to elucidate the concomitant molecular signaling events that are pivotal for our understanding of the signaling of VPF/VEGF. Utilizing two different in vitro cell culture systems and an in vivo zebrafish model, we demonstrate that NRP-1 mediates VPF/VEGF-induced EC survival independent of VEGFR-2. Furthermore, we show here a novel mechanism for NRP-1-specific control of the anti-apoptotic pathway in EC through involvement of the NRP-1-interacting protein (NIP/GIPC) in the activation of PI-3K/Akt and subsequent inactivation of p53 pathways and FoxOs, as well as activation of p21. This study, by elucidating the mechanisms that govern VPF/VEGF-induced EC survival signaling via NRP-1, contributes to a better understanding of molecular mechanisms of cardiovascular development and disease and widens the possibilities for better therapeutic targets.
References
[1]
Gobe G, Browning J, Howard T, Hogg N, Winterford C, et al. (1997) Apoptosis occurs in endothelial cells during hypertension-induced microvascular rarefaction. J Struct Biol 118(1): 63–72.
[2]
Dimmeler S, Hermann C, Zeiher AM (1998) Apoptosis of endothelial cells. Contribution to the pathophysiology of atherosclerosis? Eur Cytokine Netw 9(4): 697–698.
[3]
Tricot O, Mallat Z, Heymes C, Belmin J, Leseche G, et al. (2000) Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation 101(21): 2450–2453.
[4]
Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, et al. (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. Faseb J 15(2): 427–438.
Stemerman MB, Ross R (1972) Experimental arteriosclerosis. I. Fibrous plaque formation in primates, an electron microscope study. J Exp Med 136(4): 769–789.
[7]
Ross R, Glomset J, Harker L (1977) Response to injury and atherogenesis. Am J Pathol 86(3): 675–684.
[8]
Hansson GK (1994) Immunological control mechanisms in plaque formation. Basic Res Cardiol 89 Suppl 1: 41–46.
[9]
Rossig L, Dimmeler S, Zeiher AM (2001) Apoptosis in the vascular wall and atherosclerosis. Basic Res Cardiol 96(1): 11–22.
[10]
Littlewood TD, Bennett MR (2003) Apoptotic cell death in atherosclerosis. Curr Opin Lipidol 14(5): 469–475.
[11]
Waltenberger J (1997) Modulation of growth factor action: implications for the treatment of cardiovascular diseases. Circulation 96(11): 4083–4094.
[12]
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1(1): 27–31.
[13]
Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29(6 Suppl 16): 10.
[14]
Soker S, Fidder H, Neufeld G, Klagsbrun M (1996) Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 271(10): 5761–5767.
[15]
Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, et al. (2000) Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc Natl Acad Sci U S A 97(6): 2573–2578.
[16]
Wang L, Zeng H, Wang P, Soker S, Mukhopadhyay D (2003) Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem 278(49): 48848–48860.
[17]
Murga M, Fernandez-Capetillo O, Tosato G (2005) Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood 105(5): 1992–1999.
[18]
Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, et al. (2007) Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11(1): 53–67.
[19]
Wang L, Mukhopadhyay D, Xu X (2006) C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. Faseb J 20(9): 1513–1515.
[20]
Alon T, Hemo I, Itin A, Pe'er J, Stone J, et al. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1(10): 1024–1028.
[21]
Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, et al. (1998) Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 95(18): 10820–10825.
[22]
Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, et al. (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273(46): 30336–30343.
Yilmaz A, Kliche S, Mayr-Beyrle U, Fellbrich G, Waltenberger J (2003) p38 MAPK inhibition is critically involved in VEGFR-2-mediated endothelial cell survival. Biochem Biophys Res Commun 306(3): 730–736.
[25]
Pauli SA, Tang H, Wang J, Bohlen P, Posser R, et al. (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology 146(3): 1301–1311.
[26]
Brusselmans K, Bono F, Collen D, Herbert JM, Carmeliet P, et al. (2005) A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia. J Biol Chem 280(5): 3493–3499.
[27]
Barr MP, Byrne AM, Duffy AM, Condron CM, Devocelle M, et al. (2005) A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells. Br J Cancer 92(2): 328–333.
[28]
Soker S, Gollamudi-Payne S, Fidder H, Charmahelli H, Klagsbrun M (1997) Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J Biol Chem 272(50): 31582–31588.
[29]
Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, et al. (2001) Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 61(15): 5736–5740.
[30]
Bachelder RE, Lipscomb EA, Lin X, Wendt MA, Chadborn NH, et al. (2003) Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res 63(17): 5230–5233.
[31]
Yao R, Cooper GM (1995) Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267(5206): 2003–2006.
[32]
Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, et al. (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275(5300): 661–665.
[33]
Fruman DA, Meyers RE, Cantley LC (1998) Phosphoinositide kinases. Annu Rev Biochem 67: 481–507.
[34]
Vanhaesebroeck B, Waterfield MD (1999) Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253(1): 239–254.
[35]
Ekker SC, Larson JD (2001) Morphant technology in model developmental systems. Genesis 30(3): 89–93.
[36]
Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M (2002) Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 21(8): 1299–1303.
[37]
Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, et al. (2003) A unified model for apical caspase activation. Mol Cell 11(2): 529–541.
[38]
Khosravi-Far R, Esposti MD (2004) Death receptor signals to mitochondria. Cancer Biol Ther 3(11): 1051–1057.
[39]
Nakamura Y (2004) Isolation of p53-target genes and their functional analysis. Cancer Sci 95(1): 7–11.
[40]
Liedtke C, Groger N, Manns MP, Trautwein C (2003) The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism. J Biol Chem 278(30): 27593–27604.
[41]
Chang DW, Ditsworth D, Liu H, Srinivasula SM, Alnemri ES, et al. (2003) Oligomerization is a general mechanism for the activation of apoptosis initiator and inflammatory procaspases. J Biol Chem 278(19): 16466–16469.
[42]
Li Y, Dowbenko D, Lasky LA (2002) AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 277(13): 11352–11361.
[43]
Biggs WH 3rd, Meisenhelder J, Hunter T, Cavenee WK, Arden KC (1999) Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A 96(13): 7421–7426.
[44]
Nakae J, Park BC, Accili D (1999) Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem 274(23): 15982–15985.
[45]
Alvarez B, Martinez AC, Burgering BM, Carrera AC (2001) Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 413(6857): 744–747.
[46]
Potente M, Fisslthaler B, Busse R, Fleming I (2003) 11,12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1. J Biol Chem 278(32): 29619–29625.
[47]
Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, et al. (1999) Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398(6728): 630–634.
[48]
Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92(6): 735–745.
[49]
Downward J (1995) Signal transduction. A target for PI(3) kinase. Nature 376(6541): 553–554.
[50]
Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, et al. (1997) The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 11(6): 701–713.
[51]
Parrizas M, Saltiel AR, LeRoith D (1997) Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 272(1): 154–161.
[52]
Kohn AD, Kovacina KS, Roth RA (1995) Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing ser/thr kinase. Embo J 14(17): 4288–4295.
[53]
Klippel A, Escobedo JA, Hirano M, Williams LT (1994) The interaction of small domains between the subunits of phosphatidylinositol 3-kinase determines enzyme activity. Mol Cell Biol 14(4): 2675–2685.
[54]
Guo D, Jia Q, Song HY, Warren RS, Donner DB (1995) Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270(12): 6729–6733.
[55]
Raj K, Ogston P, Beard P (2001) Virus-mediated killing of cells that lack p53 activity. Nature 412(6850): 914–917.
[56]
Gu Y, Turck CW, Morgan DO (1993) Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366(6456): 707–710.
[57]
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk–interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75(4): 805–816.
[58]
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366(6456): 701–704.
[59]
Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, et al. (1994) Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54(13): 3391–3395.
[60]
Zeng YX, el-Deiry WS (1996) Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 12(7): 1557–1564.
[61]
Johannessen LE, Knardal SL, Madshus IH (1999) Epidermal growth factor increases the level of the cyclin-dependent kinase (CDK) inhibitor p21/CIP1 (CDK-interacting protein 1) in A431 cells by increasing the half-lives of the p21/CIP1 transcript and the p21/CIP1 protein. Biochem J 337 ( Pt 3): 599–606.
[62]
Fukuchi K, Watanabe H, Tomoyasu S, Ichimura S, Tatsumi K, et al. (2000) Phosphatidylinositol 3-kinase inhibitors, Wortmannin or LY294002, inhibited accumulation of p21 protein after gamma-irradiation by stabilization of the protein. Biochim Biophys Acta 1496(2–3): 207–220.
[63]
Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, et al. (2000) The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 60(19): 5390–5394.
[64]
Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, et al. (1995) High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res 1(9): 1051–1057.
[65]
Erber R, Klein W, Andl T, Enders C, Born AI, et al. (1997) Aberrant p21(CIP1/WAF1)protein accumulation in head-and-neck cancer. Int J Cancer 74(4): 383–389.
[66]
Weiss RH, Joo A, Randour C (2000) p21(Waf1/Cip1) is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem 275(14): 10285–10290.
[67]
Barboule N, Chadebech P, Baldin V, Vidal S, Valette A (1997) Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene 15(23): 2867–2875.
[68]
Gorospe M, Wang X, Holbrook NJ (1999) Functional role of p21 during the cellular response to stress. Gene Expr 7(4–6): 377–385.
[69]
Lawlor MA, Rotwein P (2000) Insulin-like growth factor-mediated muscle cell survival: central roles for Akt and cyclin-dependent kinase inhibitor p21. Mol Cell Biol 20(23): 8983–8995.
[70]
Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, et al. (2000) Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287(5459): 1804–1808.
[71]
Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, et al. (1999) Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. Embo J 18(5): 1223–1234.
[72]
Zhang Y, Fujita N, Tsuruo T (1999) Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene 18(5): 1131–1138.
[73]
Sohn D, Essmann F, Schulze-Osthoff K, Janicke RU (2006) p21 blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of cyclin-dependent kinase-mediated caspase-9 activation. Cancer Res 66(23): 11254–11262.
[74]
You H, Jang Y, You-Ten AI, Okada H, Liepa J, et al. (2004) p53-dependent inhibition of FKHRL1 in response to DNA damage through protein kinase SGK1. Proc Natl Acad Sci U S A 101(39): 14057–14062.
[75]
Potente M, Urbich C, Sasaki K, Hofmann WK, Heeschen C, et al. (2005) Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest 115(9): 2382–2392.
[76]
Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, et al. (2003) FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 278(50): 49795–49805.
[77]
Langheinrich U, Hennen E, Stott G, Vacun G (2002) Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling. Curr Biol 12(23): 2023–2028.
[78]
Suhara T, Kim HS, Kirshenbaum LA, Walsh K (2002) Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol Cell Biol 22(2): 680–691.
[79]
Skurk C, Maatz H, Kim HS, Yang J, Abid MR, et al. (2004) The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem 279(2): 1513–1525.
[80]
Liu JW, Chandra D, Rudd MD, Butler AP, Pallotta V, et al. (2005) Induction of prosurvival molecules by apoptotic stimuli: involvement of FOXO3a and ROS. Oncogene 24(12): 2020–2031.
[81]
Haffter P, Granato M, Brand M, Mullins MC, Hammerschmidt M, et al. (1996) The identification of genes with unique and essential functions in the development of the zebrafish, Danio rerio. Development 123: 1–36.
[82]
Lawson ND, Weinstein BM (2002) In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 248(2): 307–318.
[83]
Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF (1995) Stages of embryonic development of the zebrafish. Dev Dyn 203(3): 253–310.
